Organon & vs Zoetis
Zoetis is the larger business, with $9.47bn of revenue in fiscal 2025 against $6.22bn for Organon & (1.5 times as much). Zoetis grew faster (2.3% against -2.9%). Zoetis kept more of each dollar of sales as profit: a net margin of 28.2% against 3.0%. Zoetis carries less debt relative to equity (267.9% against 1149.5%).
| Latest fiscal year | Organon &OGN, 2025 | ZoetisZTS, 2025 |
|---|---|---|
| Revenue | $6.22bn | $9.47bn |
| Revenue growth | -2.9% | 2.3% |
| Net income | $187m | $2.67bn |
| Operating margin | — | — |
| Net margin | 3.0% | 28.2% |
| Return on equity | 30.6% | 65.3% |
| Free cash flow | $538m | $2.28bn |
| Cash | $574m | $2.45bn |
| Total debt | $8.64bn | $9.15bn |
| Debt to equity | 1149.5% | 267.9% |
| Dividend per share | $0.34 | $2.03 |
| Dividend yield | 0.6% | 2.6% |
| Share buybacks | — | $3.23bn |
| Employees | 10,000 | — |
| Market value | $3.64bn | $34.37bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 56 (Moderate) | 93 (Strong) |
| Insider trades, 12 months | 2 buys, 2 sales | 3 buys, 2 sales |